So it’s always interesting as you enter into crowded markets. But that being said, we know, as we start targeting some of these radiosensitive tumors, we don’t want to shy away from an area just because there is competition. Competition is good and the ability to give patients and physicians choices on treatment. It’s something that is corner stone in the pharmaceutical market.
Lukas Shumway: Okay. And then, if I could, one more for the GD2-SADA Part A, what is your measure for success? Like, what’s your go, no-go that you’re looking for?
Michael Rossi: Well, for us, it’s a safety study, right? So we haven’t had any dose limiting toxicities to date. So for us, it’s making sure that we continue to see a safe drug that could potentially be efficacious and that we’re also seeing continuing to paint the tumors and being a basket trial, we’re also — this isn’t a situation where we just took a protein, inject it into healthy humans, and determined that, it is safe on its own. We’re also injecting the radioactivity with it, which is giving us additional information on tumor expression, tumor uptake as well as what cancers may be more susceptible or more — have a better affinity for GD2-SADA. So it’s really an information collecting and it allows us to then remove some variables as we move into Phase II. But we’re very happy with how the safety trial is progressing.
Lukas Shumway: Okay, thanks so much.
Michael Rossi: Thanks, Luke.
Operator: Thank you. Ladies and gentlemen, that concludes our question-and-answer session. I’ll turn the floor back to Mr. Rossi for final comments.
Michael Rossi: Very good. I appreciate it. Thank you, everybody, for participating in today’s fourth quarter and full-year 2023 earnings call and for your continued interest in Y-mAbs. With the strong financial foundation and the right team in place, we believe Y-mAbs is positioned to continue improving outcomes for patients and families impacted by childhood cancers, while at the same time potentially shifting the treatment paradigm for a variety of both pediatric and adult cancers with our novel pretargeted radioimmunotherapy platform. We’re very encouraged by the early data we’ve seen so far and incredibly excited about the potential of SADA PRIT to emerge as the preferred radiopharmaceutical treatment platform of choice for physicians and their patients. We look forward to providing further updates throughout the year and seeing many of you at upcoming conferences. Thank you and have a great day.
Operator: Thank you. This concludes today’s conference call. You may disconnect your lines at this time. Thank you for your participation.
